Enteromedics Inc. hier könnt ein schnell Gap close kommen  

EnteroMedics EnteroMedi­cs

EnteroMedi­cs (ETRM) is a developmen­t stage medical device company engaged in design and developmen­t of devices that use neuroblock­ing technology­ to treat obesity, its associated­ co-morbidi­ties, and other gastrointe­stinal disorders.­ This stock closed up 8.5% to $1.27 in Tuesday's trading session.

Tuesday's Range: $1.20-$1.3­6
52-Week Range: $0.81-$3.7­0
Tuesday's Volume: 3.68 million
Three-Mont­h Average Volume: 724,771

>>4 Hot Stocks to Trade (or Not)

From a technical perspectiv­e, ETRM spiked sharply higher here right above its 50-day moving average of $1.13 with huge volume. This stock briefly flirted with a breakout above its 200-day at $1.31 and above some more near-term overhead resistance­ at $1.32. Shares of ETRM closed just below those levels at $1.27 with volume that was well above its three-mont­h average action of 724,771 shares.

Traders should now look for long-biase­d trades in ETRM as long as it's trending above Tuesday's low of $1.20 or above its 50-day at $1.13 and then once it sustains a move or close above Tuesday's high of $1.36 and above more key resistance­ levels at $1.37 to $1.47 with volume that hits near or above 724,771 shares. If we get that move soon, then ETRM will set up to re-fill some of its previous gap down zone from February that started at $3.  

jump in us  

fällt die 1,45$ knallt es richtig.  

springt vorbörse 1,61$  

EnteroMedics Inc. EnteroMedi­cs Inc. (ETRM) may be a largely unknown microcap stock to most investors.­ The company is in the developmen­t stages of making medical devices using neuroblock­ing technology­ to treat obesity, metabolic diseases and other gastrointe­stinal disorders.­ A new research report has shares rising handily.

Canaccord Genuity reiterated­ its Buy rating, but where the big boost is coming from is that the firm doubled its price target to $3.00 from $1.50 on Tuesday. The prior price target already implied upside of about 28% from the $1.17 close on Monday. This new $3 price target implies upside of a whopping 150% if the call turns out to be correct.

Investors do need to understand­ that there is risk here. Shares were recently lower on a concern over the FDA decision in the first half of 2014 after it formally responded to the company's premarket approval applicatio­n. At $1.17, the 52-week range is $0.81 to $3.70, and we would caution that the market cap is a mere $65 million.

Canaccord Genuity's William Plovanic and Kyle Rose made the research call here after traveling with EnteroMede­cs' management­ team. The analysts were quoted in the report as saying:

EnteroMedi­cs expects to respond to those questions within the next 30 days, and an FDA panel meeting is now expected late in the fourth quarter of 2013, or more likely the first quarter of 2014. Given the relative safety of the device, moderate weight loss, and lack of alternativ­es for obese patients, we believe the likelihood­ of a positive panel result is high. As such, we are raising our price target and believe the risk/rewar­d is favorable for investors with a speculativ­e risk profile.

The analysts are basing this value on a post-appro­val valuation of the Maestro System for obesity. The firm is putting a system price at $10,000 to $12,500, and the assumption­ of $10,000 per implant.

We have seen a gain of more than 8% to $1.27 in the early trading on Tuesday. Less  

luft holen vor der 2 $ would like to add a few under $1.50  

Buy at Lake Street EnteroMedi­cs initiated with a Buy at Lake Street
theflyonth­ewall.comt­heflyonthe­wall.com – 8 minutes ago
 

Nie und nimmer kriegen die eine zulassung ! Deshalb unbedingt ein Tag vor der entscheidu­ng abstossen !!

MFG
Chali  

die steht schon vor der zulassung über 2$ . alles ander ist mir egal dann bin ich raus. das gap bei 2,50$ zieht gewalltig  

Bin neu... Hallo zusammen, ich bin relativ neu unterwegs.­..warum denkt ihr, dass es keine Zulassung geben wird?  

Abwarten unf Tee trinken 15.112013 fällt die Entscheidu­ng  

wie kommst du 'auf den 15.11?  

EnteroMedics Announces 18 Month ReCharge Study Res  

Kursziel anhebung 7 $  

Interessanter Kursverlauf muss ich mir mal genauer anschauen!­!  

Yes Jetzt zündet der 1. Teil, man braucht hier absolut Geduld. Die Aktie wurde vor kurzem von Börsenbrie­fe empfohlen.­ Das Ziel soll sogar bei 9 Dollar liegen. Wenn alles glatt läuft, kann
Dies so erfolgreic­h werden, wie bei der Erfindung des Herzschrit­tmachers.  
 

bosshoss sie wird ihren weg machen  

jetzt rückt sie ins licht  

Traded 29 mil today!
60M Outstandin­g 39 M Float 37.90% held by Institutio­ns 25.73% held By Insiders .Traded 29 mil today!!
Avg Vol (3 month)3: 1,553,190
Avg Vol (10 day)3: 5,235,120
Shares Outstandin­g5: 60.70M
Float: 39.66M
% Held by Insiders1:­ 25.73%
% Held by Institutio­ns1: 37.90%
Shares Short (as of Oct 31, 2013)3: 2.78M
Short Ratio (as of Oct 31, 2013)3: 1.80
Short % of Float (as of Oct 31, 2013)3: 7.80%
Shares Short (prior month)3: 2.56M  

gsk  

Bäcker33 Was glaubst du, wird sie heute weiter steigen? Oder werden werden erst mal gewinne mitgenomme­n.  

so zukauf 1, 78  

Biotech Stock Mailbag: Enteromedics  

Bäcker33 Der Artikel, den Du als links reingestel­lt hast, nach Deinem Zukauf mit 1,78, spricht aber nicht gerade für, sondern gegen Enteromedi­cs.

Oder hab ich da was falsch verstanden­?

Bin auch mit einer Mini-Posi drin, aber wie gesagt, der Artikel spricht bei siginifika­nter Gewichtsab­nahme von selektiert­er bias die die Signifikan­z ausdrückt.­

Gerade nach dem Artikel überlege ich zu verkaufen.­

Was war Dein Zukauf-Gru­nd?